Full Text View
Tabular View
No Study Results Posted
Related Studies
A Randomized Controlled Trial on Antibiotic Prophylaxis in Children With Vesico-Ureteral Reflux
This study has been completed.
First Received: September 28, 2006   No Changes Posted
Sponsor: IRCCS Burlo Garofolo
Information provided by: IRCCS Burlo Garofolo
ClinicalTrials.gov Identifier: NCT00382343
  Purpose

The aim of this study is to assess the effectiveness of antibiotic prophylaxis in preventing pyelonephritis and in avoiding the appearance of new scars in a sample of children under 36 months with vesico-ureteral reflux (VUR).


Condition Intervention Phase
Pyelonephritis
Renal Scars
Drug: sulfamethoxazole/trimethoprim or nitrofurantoin prophylaxis
Phase IV

Study Type: Interventional
Study Design: Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: Antibiotic Prophylaxis After Acute Pyelonephritis for Prevention of Urinary Tract Infections in Children With Vesico-Ureteral Reflux.

Resource links provided by NLM:


Further study details as provided by IRCCS Burlo Garofolo:

Primary Outcome Measures:
  • Recurrence of pyelonephritis
  • Renal scars

Secondary Outcome Measures:
  • Persistence of vesico-ureteral reflux

Estimated Enrollment: 96
Study Start Date: November 1999
Estimated Study Completion Date: May 2006
Detailed Description:

In recent years, the effectiveness of continuous antibiotic prophylaxis in children with vesico-ureteral reflux (VUR) has been intensely discussed. The question is not only whether antibiotics are effective in preventing recurrent urinary tract infections (UTI), but also whether they alter the natural history of disease and help to prevent the appearance of new kidneys scars. The evidence on the effectiveness of antibiotic prophylaxis is scanty: randomised controlled trials (RCT) published until now are poorly designed and carried out in very heterogeneous samples of children, i.e. spanning from 6 months to 14-18 years of age and pooling patients with and without VUR. A recently updated Cochrane Systematic Review concludes that high quality RCTs are needed to determine the effectiveness of long-term antibiotics for the prevention of UTIs in susceptible children. Moreover, the presence of VUR has not been firmly shown to be a risk factor for recurrence of pyelonephritis, and a direct association between VUR and the presence of scars or the appearance of new scars has not been demonstrated; there is just an association between VUR of grade IV-V and prenatal renal dysplasia, almost exclusively in male infants. In spite of this uncertainty, several practice guidelines recommend long term antibiotic prophylaxis in children with different degrees of VUR.

The aim of this study is to assess the effectiveness of antibiotic prophylaxis in preventing pyelonephritis and in avoiding the appearance of new scars in a sample of children under 36 months with VUR.

Comparison: In a multicentre trial, 100 patients with VUR diagnosed with cystourethrography after a first episode of acute pyelonephritis or for prenatal evidence of pyelectasia will be assigned randomly to receive prophylaxis or not. Randomization will be carried out using a centralized minimization procedure to balance for sex, age group and VUR grade.

  Eligibility

Ages Eligible for Study:   up to 30 Months
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • presence of vesico-ureteral reflux (VUR) grade II, III or IV, based on the International Classification, mono or bilateral, diagnosed between one day and 30 months of age after a first episode of acute pyelonephritis, or after birth during diagnostic procedures planned as a consequence of prenatal ultrasonographic evidence of pyelectasia.

Exclusion Criteria:

  • previous episodes of urinary tract infection (UTI), even if only suspected (e.g. an episode of fever treated with antibiotics without performing urine culture);
  • VUR grade I, because of the high probability of rapid spontaneous resolution;
  • VUR grade V, as requested by the Technical Scientific Committee, concerned by the high incidence of associated renal dysplasia;
  • recurrence of acute pyelonephritis before the first dimercaptosuccinic acid (DMSA) renal scan, if this was positive for scars.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00382343

Locations
Italy
Sant'Orsola Hospital
Bologna, Italy, 48138
Bufalini Hospital
Cesena, Italy, 47023
Santa Maria degli Angeli Hospital
Pordenone, Italy, 33170
Institute of Child Health IRCCS Burlo Garofolo
Trieste, Italy, 34137
Italy, Gorizia
San Polo Hospital
Monfalcone, Gorizia, Italy, 34170
Italy, Udine
Sant'Antonio Abate Hospital
Tolmezzo, Udine, Italy, 33028
San Daniele Hospital
San Daniele, Udine, Italy, 33100
Sponsors and Collaborators
IRCCS Burlo Garofolo
Investigators
Principal Investigator: Marco Pennesi, MD Institute of Child Health IRCCS Burlo Garofolo, Trieste, Italy
  More Information

No publications provided by IRCCS Burlo Garofolo

Additional publications automatically indexed to this study by National Clinical Trials Identifier (NCT ID):
Study ID Numbers: RC 35/00
Study First Received: September 28, 2006
Last Updated: September 28, 2006
ClinicalTrials.gov Identifier: NCT00382343     History of Changes
Health Authority: Italy: Ministry of Health

Keywords provided by IRCCS Burlo Garofolo:
Prevention
Pyelonephritis
Renal scars
Vesico-ureteral reflux
Dimercaptosuccinic acid renal scan (DMSA)

Additional relevant MeSH terms:
Anti-Infective Agents
Trimethoprim
Antiprotozoal Agents
Molecular Mechanisms of Pharmacological Action
Pyelonephritis
Urinary Tract Infections
Trimethoprim-Sulfamethoxazole Combination
Infection
Renal Agents
Pyelitis
Anti-Bacterial Agents
Vesico-Ureteral Reflux
Antimalarials
Antiparasitic Agents
Nitrofurantoin
Urologic Diseases
Therapeutic Uses
Kidney Diseases
Sulfamethoxazole
Nephritis, Interstitial
Urinary Bladder Diseases
Anti-Infective Agents, Urinary
Enzyme Inhibitors
Folic Acid Antagonists
Pharmacologic Actions
Nephritis

ClinicalTrials.gov processed this record on February 08, 2010